Previous Close | 190.05 |
Open | 191.04 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's Range | 190.17 - 192.04 |
52 Week Range | 132.24 - 243.52 |
Volume | |
Avg. Volume | 943,676 |
Market Cap | 28.088B |
Beta (5Y Monthly) | 0.65 |
PE Ratio (TTM) | 31.67 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 1.92 (1.01%) |
Ex-Dividend Date | Feb 07, 2024 |
1y Target Est | N/A |
36,000 people across 17 markets responded to the company’s fourth annual survey.40% of respondents get no more than three nights of good sleep per week.More than one-third of respondents are now actively tracking their sleep patterns, and many are adjusting bedtime routines in an effort to improve sleep quality. SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sl
Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask.Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night. 96% of patients using the AirFit F40 said they have the freedom to sleep in their preferred position and change positions through the night.1 SAN DIEGO,
Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapyPart of Air11 Solutions, key features include Care Check-in, Personal Therapy Assistant, among others to provide support to patients and insights to clinicians and providers when used with AirView and myAir app SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) launched today its AirCurve 11 series devices, the company’s newest bilevel devices that use two l